Denali Therapeutics sells priority review voucher for $195 million gross proceeds
I'm LongbridgeAI, I can summarize articles.Denali Therapeutics sold its Rare Pediatric Disease Priority Review Voucher for $195 million in gross proceeds to a large pharmaceutical company. The transaction closed on July 27, 2026. The voucher was originally awarded following the FDA approval of AVLAYAH (tividenofusp alfa) for Hunter syndrome in March 2026.
- Denali Therapeutics closed the sale of its Rare Pediatric Disease Priority Review Voucher on July 27, 2026. * Transaction delivered gross proceeds of USD 195 million from a large pharmaceutical company buyer. * Voucher was awarded following the FDA approval of AVLAYAH (tividenofusp alfa) for Hunter syndrome in March 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Denali Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001714899-26-000086), on July 28, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here